5-[1-(4-bromobutyl)cyclopentyl]resorcinol | 941583-87-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 5-[1-(4-bromobutyl)cyclopentyl]resorcinol
• 英文别名: 5-[1-(4-Bromobutyl)cyclopentyl]benzene-1,3-diol
• CAS: 941583-87-5
• 化学式: C₁₅H₂₁BrO₂
• 分子量: 313.235
• InChiKey: GYZKZDOMWFIBGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3,5-dimethoxy-1-[1-(4-phenoxybutyl)cyclopentyl]benzene 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以535 mg的产率得到5-[1-(4-bromobutyl)cyclopentyl]resorcinol
  参考文献：
  名称：

  Novel 1′,1′-Chain Substituted Hexahydrocannabinols: 9β-Hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a Highly Potent Cannabinoid Receptor 1 (CB1) Agonist

  摘要：

  In pursuit of a more detailed understanding of the structural requirements for the key side chain cannabinoid pharmacophore, we have extended our SA R to cover a variety of conformationally modified side chains within the 9-keto and 9-hydroxyl tricyclic structures. OF the compounds described here. those with a seven-atom long side chain substituted with a cyclopentyl ring at Cl' position have very high affinities For both CB1 and CB2 (0.97 nM < K-1 < 5.25 nM), with no preference for either of the two receptors. However, presence of the smaller cyclobutyl group at the Cl' position leads to an optimal affinity and selectivity interaction with CB1. Thus, two of the Cl'-cyclobutyl analogues, namely. (6a R.10aR R)-3-(1-hexyl-cyclobut-1-y1)-6,6a,7,8, 10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo-[b,d]pyran-9-one and (6aR,9R, 10aR)-3-(1-hexyl-cyclobut-1-yl)-6a,7,8,9,10, 10a-hexahydro-6.6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol (7e-beta, AM2389), exhibited remarkably high affinities (0.84 and 0.16 nM respectively) and significant selectivities (16- and 26-fold, respectively) for CB1. Compound 7e-beta was found to exhibit exceptionally high in vitro and in vivo potency with a relatively long duration of action.

  DOI：

  10.1021/jm100641g

文献信息

• ONE-STEP FLOW-MEDIATED SYNTHESIS OF CANNABIDIOL (CBD) AND DERIVATIVES
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US20200325091A1

  公开（公告）日：2020-10-15

  Herein are described apparatus and processes for the preparation of cannabinoids, such as cannabidiol (CBD) and derivatives thereof. The apparatus and processes described can be used for the one-step, flow-mediated synthesis of cannabidiol and derivatives with improved overall yield, material throughput, and product purity relative to batch processes.

  本文描述了用于制备大麻素（如大麻二酚CBD）及其衍生物的装置和工艺。所描述的装置和工艺可用于一步法、流程介导的合成大麻二酚及其衍生物，相对于批处理过程，具有更高的总产量、材料通过量和产品纯度。
• One-step flow-mediated synthesis of cannabidiol (CBD) and derivatives
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US10981850B2

  公开（公告）日：2021-04-20

  Herein are described apparatus and processes for the preparation of cannabinoids, such as cannabidiol (CBD) and derivatives thereof. The apparatus and processes described can be used for the one-step, flow-mediated synthesis of cannabidiol and derivatives with improved overall yield, material throughput, and product purity relative to batch processes.

  本文描述了制备大麻素（如大麻二酚（CBD）及其衍生物）的设备和工艺。所述设备和工艺可用于一步法、流动介导合成大麻二酚及其衍生物，与批量工艺相比，总体产量、材料吞吐量和产品纯度均有所提高。
• [EN] ONE-STEP FLOW-MEDIATED SYNTHESIS OF CANNABIDIOL (CBD) AND DERIVATIVES<br/>[FR] SYNTHÈSE À MÉDIATION PAR L'ÉCOULEMENT EN UNE ÉTAPE DE CANNABIDIOL (CBD) ET DE SES DÉRIVÉS
  申请人：UNIV BOSTON

  公开号：WO2020214574A1

  公开（公告）日：2020-10-22

  Herein are described apparatus and processes for the preparation of cannabinoids, such as cannabidiol (CBD) and derivatives thereof. The apparatus and processes described can be used for the one-step, flow-mediated synthesis of cannabidiol and derivatives with improved overall yield, material throughput, and product purity relative to batch processes.
• Novel 1′,1′-Chain Substituted Hexahydrocannabinols: 9β-Hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a Highly Potent Cannabinoid Receptor 1 (CB1) Agonist
  作者：Spyros P. Nikas、Shakiru O. Alapafuja、Ioannis Papanastasiou、Carol A. Paronis、Vidyanand G. Shukla、Demetris P. Papahatjis、Anna L. Bowman、Aneetha Halikhedkar、Xiuwen Han、Alexandros Makriyannis

  DOI：10.1021/jm100641g

  日期：2010.10.14

  In pursuit of a more detailed understanding of the structural requirements for the key side chain cannabinoid pharmacophore, we have extended our SA R to cover a variety of conformationally modified side chains within the 9-keto and 9-hydroxyl tricyclic structures. OF the compounds described here. those with a seven-atom long side chain substituted with a cyclopentyl ring at Cl' position have very high affinities For both CB1 and CB2 (0.97 nM < K-1 < 5.25 nM), with no preference for either of the two receptors. However, presence of the smaller cyclobutyl group at the Cl' position leads to an optimal affinity and selectivity interaction with CB1. Thus, two of the Cl'-cyclobutyl analogues, namely. (6a R.10aR R)-3-(1-hexyl-cyclobut-1-y1)-6,6a,7,8, 10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo-[b,d]pyran-9-one and (6aR,9R, 10aR)-3-(1-hexyl-cyclobut-1-yl)-6a,7,8,9,10, 10a-hexahydro-6.6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol (7e-beta, AM2389), exhibited remarkably high affinities (0.84 and 0.16 nM respectively) and significant selectivities (16- and 26-fold, respectively) for CB1. Compound 7e-beta was found to exhibit exceptionally high in vitro and in vivo potency with a relatively long duration of action.